COVID-19: An Update on therapeutics and Clinical trials

Kamla Pathak; Devender Pathak; Ramakant Yadav; Raj Kumar

doi:10.25004/IJPSDR.2020.120416

Authors

Kamla Pathak Uttar Pradesh University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, India
Devender Pathak Uttar Pradesh University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, India
Ramakant Yadav Uttar Pradesh University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, India
Raj Kumar Uttar Pradesh University of Medical Sciences, Saifai, Etawah-206130, Uttar Pradesh, India

Abstract

Corona viruses are a large family of viruses that cause illness ranging from the common cold to more severe diseases. A novel coronavirus (nCoV) is a new strain that has not been previously identified in humans. On 30 January 2020, the WHO Director-General declared the novel corona virus (COVID-19) outbreak a public health emergency of international concern. Many fatalities have occurred and continue to happen. Despite staggering research efforts for therapeutics, complete cure is still a distant dream. The write up updates the treatment approaches utilized in clinical settings across the globe and the clinical trials registered in the Federal register and WHO register for drugs and vaccines to combat the pandemic.

Keywords:

COVID-19, therapeutics, clinical trials, vaccines, traditional approaches

DOI

https://doi.org/10.25004/IJPSDR.2020.120416

References

Saey TH. Explainer: What is a coronavirus? Society for Science & the Public, which publishes Science News for Students. January 23, 2020.

World Health Organization, Coronvirus disease 2019 (COVID-19) Situation Report-90 (April 19, 2020). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed April 19, 2020.

Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nature Rev Microbiol. 2019; 17:181–192.

https://www.clinicaltrialsarena.com/news/china-approves-favilavir-covid-19/ exceed on 28/02/2020 12:19

https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-3-18-2020.pdf Accessed on 16th April 2020.

Coronavirus disease 2019 (COVID-19) Situation Report – 84, Data as received by WHO from national authorities by 10:00 CET, 13 April 2020.

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19), 16-24 February 2020.

Wu Z, mcGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Feb 24; doi: 10.1001/jama.2020.2648.

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance 13 March 2020.

Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD, Features, evaluation and treatment coronavirus (COVID-19), Treasure Island (FL): Statpearls Publishing; 2020 Jan.

Handbook of COVID-19 Prevention and Treatment, First Affiliated Hospital, Zhejiang University School of Medicine, 2020, 24-25.

CT provides best diagnosis for COVID-19, Science news, Radiological Society of North America, 26 February 2020.

Wahidi MM, Lamb C, Murgu S, et al. American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 Infection. J Bronchology Interv Pulmonol. March 2020, Ahead of print, doi: 10.1097/LBR.0000000000000681.

Popov D. Treatment of Covid-19 Infection. A rationale for current and future pharmacological approach. EC Pulmonol Resp Med. 2020; 9: 38-58.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14:58-60.

Potential cheap and effective Drug for COVID-19, https://www.researchgate.net/post /Potential_Cheap_and_effective_Drug_for_COVID-19. Accessed 2 June 2020.

Gordon CJ, Tchesnoaov EP, Wulner E, Perry JK, Fang YJ, Danielle PP, Gotte M. The antiviral compound remedesivir potently inhibits RNA dependent RNA polymerase from Middle East respiratory syndrome. J Biol Chem. 2020; 295: 4773-4779.

Reidl J, Eduard Monsó E. Glucocorticoids and antibiotics, how do they get together? EMBO Mol Med. 2015; 7: 992–993.

Holten K B, Onusko EM. Appropriate prescribing of oral beta-lactam antibiotics. Am Fam Physician. 2000; 62:611-620.

Fair RJ, TorY. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014; 6: 25–64.

Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Dupont HervéTissot, Honoré Sté, Stein A, Million M, Colson P, La Scola B, Veit Vé, Jacquier A, Deharo J-C, Drancourt M, Fournier PE, Rolain J-M, Brouqui P, Raoult D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Disease. 2020; doi: https://doi.org/10.1016/.j.tmaid.2020.101663.

Zhou W, Li H, Zhang Y, Huang M, He Q, Li P, Zhang F, Shi Y, Su X. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with non-neutropenic invasive pulmonary. Aspergillosis, J Clin Microbiol. 2017; 55: 2153–2161.

Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014; 5: 161–169.

Jenks JD, Hoenig M. Treatment of Aspergillosis, J Fungi (Basel). 2018; 4: 98-103.

https://clinicaltrials.gov/ct2/results?cond=COVID-19, Accessed 8 Jun 2020.

https://clinicaltrials.gov/ct2/who_table, Accessed 8 Jun 2020.

Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patient with COVID-19 patients.JAMA, 2020; 323 : 1582-1589.

Duan K, Lui B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad Sci USA. 2020; 117: 9490-9496.

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J. Med. Virol. 2020;1-9, https://doi.org/10.1002/jmv.25961.

Regeneron announces important advances in novel covid-19 antibody program, March 17, 2020, https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody, Accessed 19 April 2020.

https://www.sciencemag.org/news/2020/04/these-are-answers-we-need-who-plans-global-study-discover-true-extent-coronavirus, Accessed 19April 2020.

Coomes EA, View ORCID ProfileHourmazd Haghbayan, Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis, MedRxIV, https://www.medrxiv.org/content/ 10.1101/ 2020.03.30.20048058v1 Accessed 19 April 2020.

https://www.businessinsider.in/science/news/the-first-patients-just-enrolled-in-a-trial-testing-the-arthritis-drug-actemra-against-the-coronavirus-results-are-expected-in-early-summer-/articleshow/75018790.cms, accessed 19 April 2020.

https://www.reuters.com/article/us-health-coronavirus-sanofi-fr-regenero/sanofi-regeneron-expand-testing-of-potential-coronavirus-treatment-idUSKBN21H0E8, 19 April2020.

https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1) accessed on 17th April 2020

Bacille Calmette-Guérin (BCG) vaccination and COVID-19, https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19, Accessed 19 April 2020.